SCHOFIELD, Wis., Jan. 16, 2012 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB:PMBS) is pleased to announce the appointment of Sue A. Baacke, CPA, to the position of Chief Financial Officer.
Since 2009, Baacke has served as the Corporate Controller for PuraMed BioScience, Inc. gaining extensive experience in current SEC regulatory and compliance issues. Baacke came to PuraMed after holding a supervisory position at a well-established, Wisconsin-based, Certified Public Accounting firm for more than 12 years. Other experience includes auditing, preparation and review of financial statements, individual, corporate, and partnership income tax returns, payroll, and valuation of closely-held businesses.
Baacke's appointment allows PuraMed BioScience's former CFO / COO James Higgins to expand his role as chief operating officer.
"Our aim is to surpass the growth we have experienced during the last quarter through proficient management and development of our existing and new products as we continue to expand our national footprint and build our shareholder base," said Russ Mitchell, CEO of PuraMed BioScience. "We saw a need and an opportunity to strengthen our management team and we are pleased with this appointment."
Mitchell added, "Jim Higgins has done a stellar job for us as chief financial officer, and I look forward to his continued involvement as chief operating officer going forward."
About the PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract.
LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic M, PuraMed BioScience, Inc also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
Investor Awareness, Inc.
Tony Schor or James Foy
SOURCE PuraMed BioScience, Inc.